CD200 expressing multiple myeloma cells show increased resistance against T cell-mediated cytotoxicity

Abstract

Checkpoint inhibitors have improved patients' outcome in a variety of hematologic and solid cancers, although in multiple myeloma (MM), PD-1 inhibitors have yielded only limited rates of tumor regression in early clinical trials. We therefore set out to analyze the role of CD200 which may constitute an alternative yet less well-characterized immune checkpoint. CD200 is expressed on distinct immune effector cells and can also be found in various hematologic malignancies including MM, although its physiological role remains elusive. Here, we investigated the functional role of CD200 for T cell-mediated cytotoxicity against MM cells in vitro.